Pacific Biosciences of Net Income
| PACB Stock | USD 1.82 0.10 5.81% |
As of the 10th of February, Pacific Biosciences holds the Risk Adjusted Performance of (0.01), coefficient of variation of (4,103), and Variance of 35.01. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pacific Biosciences, as well as the relationship between them.
Pacific Biosciences Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 6.1416 | Revenue | Earnings Share (2.15) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -278.9 M | -264.9 M | |
| Net Loss | -278.9 M | -264.9 M | |
| Net Loss | -282.8 M | -268.7 M | |
| Net Loss | (1.02) | (1.07) | |
| Net Income Per E B T | 0.90 | 0.70 |
Pacific | Net Income | Build AI portfolio with Pacific Stock |
Analyzing Pacific Biosciences's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Pacific Biosciences's current valuation and future prospects.
Latest Pacific Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Pacific Biosciences of over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Pacific Biosciences financial statement analysis. It represents the amount of money remaining after all of Pacific Biosciences of operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Pacific Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pacific Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (309.85 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Pacific Net Income Regression Statistics
| Arithmetic Mean | (140,130,736) | |
| Geometric Mean | 105,713,957 | |
| Coefficient Of Variation | (80.05) | |
| Mean Deviation | 95,889,540 | |
| Median | (94,465,000) | |
| Standard Deviation | 112,174,309 | |
| Sample Variance | 12583.1T | |
| Range | 343.7M | |
| R-Value | (0.75) | |
| Mean Square Error | 5892.1T | |
| R-Squared | 0.56 | |
| Significance | 0.0005 | |
| Slope | (16,638,309) | |
| Total Sum of Squares | 201329.2T |
Pacific Net Income History
Other Fundumenentals of Pacific Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Pacific Biosciences Net Income component correlations
Pacific Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Pacific Biosciences is extremely important. It helps to project a fair market value of Pacific Stock properly, considering its historical fundamentals such as Net Income. Since Pacific Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pacific Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pacific Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. Anticipated expansion of Pacific directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pacific Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (2.15) | Revenue Per Share | Quarterly Revenue Growth (0.04) | Return On Assets | Return On Equity |
Understanding Pacific Biosciences requires distinguishing between market price and book value, where the latter reflects Pacific's accounting equity. The concept of intrinsic value - what Pacific Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Pacific Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Pacific Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pacific Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Pacific Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Pacific Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Pacific Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Pacific Biosciences.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Pacific Biosciences on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Pacific Biosciences of or generate 0.0% return on investment in Pacific Biosciences over 90 days. Pacific Biosciences is related to or competes with Avanos Medical, Orthofix Medical, Si Bone, Butterfly Network, DarioHealth Corp, Iovance Biotherapeutics, and Integra LifeSciences. Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically co... More
Pacific Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Pacific Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Pacific Biosciences of upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 29.88 | |||
| Value At Risk | (8.85) | |||
| Potential Upside | 10.33 |
Pacific Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pacific Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Pacific Biosciences' standard deviation. In reality, there are many statistical measures that can use Pacific Biosciences historical prices to predict the future Pacific Biosciences' volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.28) | |||
| Total Risk Alpha | (0.81) | |||
| Treynor Ratio | (0.11) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Pacific Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Pacific Biosciences February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.10) | |||
| Mean Deviation | 4.76 | |||
| Coefficient Of Variation | (4,103) | |||
| Standard Deviation | 5.92 | |||
| Variance | 35.01 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.28) | |||
| Total Risk Alpha | (0.81) | |||
| Treynor Ratio | (0.11) | |||
| Maximum Drawdown | 29.88 | |||
| Value At Risk | (8.85) | |||
| Potential Upside | 10.33 | |||
| Skewness | 0.5292 | |||
| Kurtosis | 0.2827 |
Pacific Biosciences Backtested Returns
Pacific Biosciences appears to be dangerous, given 3 months investment horizon. Pacific Biosciences maintains Sharpe Ratio (i.e., Efficiency) of 0.041, which implies the firm had a 0.041 % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for Pacific Biosciences, which you can use to evaluate the volatility of the company. Please evaluate Pacific Biosciences' Coefficient Of Variation of (4,103), risk adjusted performance of (0.01), and Variance of 35.01 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Pacific Biosciences holds a performance score of 3. The company holds a Beta of 1.39, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pacific Biosciences will likely underperform. Please check Pacific Biosciences' standard deviation, maximum drawdown, kurtosis, as well as the relationship between the total risk alpha and potential upside , to make a quick decision on whether Pacific Biosciences' historical price patterns will revert.
Auto-correlation | 0.69 |
Good predictability
Pacific Biosciences of has good predictability. Overlapping area represents the amount of predictability between Pacific Biosciences time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Pacific Biosciences price movement. The serial correlation of 0.69 indicates that around 69.0% of current Pacific Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.69 | |
| Spearman Rank Test | -0.1 | |
| Residual Average | 0.0 | |
| Price Variance | 0.08 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Pacific Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Pacific Biosciences of reported net income of (309.85 Million). This is 190.79% lower than that of the Life Sciences Tools & Services sector and 230.13% lower than that of the Health Care industry. The net income for all United States stocks is 154.27% higher than that of the company.
Pacific Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pacific Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pacific Biosciences could also be used in its relative valuation, which is a method of valuing Pacific Biosciences by comparing valuation metrics of similar companies.Pacific Biosciences is currently under evaluation in net income category among its peers.
Pacific Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Pacific Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Pacific Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pacific Biosciences' value.| Shares | Point72 (difc) Ltd | 2025-06-30 | 2.5 M | Charles Schwab Investment Management Inc | 2025-06-30 | 2.3 M | Northern Trust Corp | 2025-06-30 | 2.2 M | Ubs Group Ag | 2025-06-30 | 2 M | Vestmark Advisory Solutions, Inc | 2025-06-30 | 1.3 M | Susquehanna International Group, Llp | 2025-06-30 | 1.3 M | Bourne Stenstrom Capital Management Inc | 2025-06-30 | 972.3 K | Xtx Topco Ltd | 2025-06-30 | 954.6 K | Hillhouse Capital Advisors, Ltd. | 2025-06-30 | 918.9 K | Ark Investment Management Llc | 2025-06-30 | 36.3 M | Blackrock Inc | 2025-06-30 | 22.7 M |
Pacific Fundamentals
| Return On Equity | -2.06 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (1.01) % | ||||
| Current Valuation | 949.39 M | ||||
| Shares Outstanding | 301.91 M | ||||
| Shares Owned By Insiders | 9.00 % | ||||
| Shares Owned By Institutions | 56.00 % | ||||
| Number Of Shares Shorted | 35.09 M | ||||
| Price To Earning | 197.88 X | ||||
| Price To Book | 15.18 X | ||||
| Price To Sales | 3.59 X | ||||
| Revenue | 154.01 M | ||||
| Gross Profit | 58.37 M | ||||
| EBITDA | (242.77 M) | ||||
| Net Income | (309.85 M) | ||||
| Cash And Equivalents | 834.34 M | ||||
| Cash Per Share | 3.69 X | ||||
| Total Debt | 672.43 M | ||||
| Debt To Equity | 1.51 % | ||||
| Current Ratio | 11.19 X | ||||
| Book Value Per Share | 0.12 X | ||||
| Cash Flow From Operations | (206.06 M) | ||||
| Short Ratio | 4.73 X | ||||
| Earnings Per Share | (2.15) X | ||||
| Price To Earnings To Growth | (0.17) X | ||||
| Target Price | 2.42 | ||||
| Number Of Employees | 575 | ||||
| Beta | 2.28 | ||||
| Market Capitalization | 555.51 M | ||||
| Total Asset | 1.26 B | ||||
| Retained Earnings | (2.15 B) | ||||
| Working Capital | 429.38 M | ||||
| Current Asset | 110.54 M | ||||
| Current Liabilities | 38.18 M | ||||
| Net Asset | 1.26 B |
About Pacific Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pacific Biosciences of's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pacific Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pacific Biosciences of based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pacific Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacific Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacific Biosciences Of Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacific Biosciences Of Stock:Check out You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. Anticipated expansion of Pacific directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pacific Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (2.15) | Revenue Per Share | Quarterly Revenue Growth (0.04) | Return On Assets | Return On Equity |
Understanding Pacific Biosciences requires distinguishing between market price and book value, where the latter reflects Pacific's accounting equity. The concept of intrinsic value - what Pacific Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Pacific Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Pacific Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pacific Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Pacific Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.